Seminars in Oncology
Volume 29, Issue 6 , Pages 589-594 , December 2002

Mistletoe and cancer: Controversies and perspectives

References 

  1. Steiner R. Geisteswissenschaft und Medizin. ed 6. Dornach, Switzerland: Rudolf Steiner Verlag; 1985;
  2. Grossarth-Maticek R, Kiene H, Baumgartner SM, et al.  Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: Prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med. 2001;7:57–74
  3. In: ed 5.  Haensel R,  Keller K,  Rimpler H, et al. editor. Hagers Handbuch der Pharmazeutischen Praxis. vol 6:Heidelberg, Germany: Springer Verlag; 1994;
  4. Samtleben R, Haito T, Hostanska K, et al.  Mistletoe lectins as immunostimulants (chemistry, pharmacology and clinic). In:  Wagner H editors. Immunomodulatory Agents from Plants. Basel, Switzerland: Birkhauser Verlag; 1999;p. 223–241
  5. Lee RT, Gabius HJ, Lee YC. Ligand binding characteristics of the major mistletoe lectin. J Biol Chem. 1992;267:23722–23727
  6. Bussing A. Mistletoe therapy and immunological research. Anticancer Drugs. 1997;8(suppl 1):S65
  7. Stein GM, Berg PA. Mistletoe extract-induced effects on immunocompetent cells: in vitro studies. Anticancer Drugs. 1997;8(suppl 1):S39–S42
  8. Gabius HJ, Andre S, Kaltner H, et al.  The mistletoe myth—Claims, reality and provable perspectives. Z Arztl Fortbild (Jena). 1996;90:103–110
  9. Franz H. Mistletoe lectins and their A and B chains. Oncology. 1986;43:23–34
  10. Elsasser-Beile U, Voss M, Schuhle R, et al.  Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro. J Clin Lab Anal. 2000;14:255–259
  11. Elsasser-Beile U, Lusebrink S, Grussenmeyer T, et al.  Comparison of the effects of various clinically applied mistletoe preparations on peripheral blood leukocytes. Arzneimittelforschung. 1998;48:1185–1189
  12. Jung ML, Baudino S, Ribereau-Gayon G, et al.  Characterization of cytotoxic proteins from mistletoe (Viscum album L.). Cancer Lett. 1990;51:103–108
  13. Park R, Kim MS, So HS, et al.  Activation of c-Jun N-terminal kinase 1 (JNK1) in mistletoe lectin II-induced apoptosis of human myeloleukemic U937 cells. Biochem Pharmacol. 2000;60:1685–1691
  14. Pae HO, Seo WG, Oh GS, et al.  Potentiation of tumor necrosis factor-alpha-induced apoptosis by mistletoe lectin. Immunopharmacol Immunotoxicol. 2000;22:697–709
  15. Bussing A, Stein GM, Pfuller U, et al.  Induction of Fas ligand (CD95L) by the toxic mistletoe lectins in human lymphocytes. Anticancer Res. 1999;19:1785–1790
  16. Bantel H, Engels IH, Voelter W, et al.  Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res. 1999;59:2083–2090
  17. Bussing A, Schietzel M. Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins. Anticancer Res. 1999;19:23–28
  18. Hostanska K, Hajto T, Spagnoli GC, et al.  A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun. 1995;14:295–304
  19. Stein G, Berg PA. Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro. Eur J Clin Pharmacol. 1994;47:33–38
  20. Rentea R, Lyon E, Hunter R. Biologic properties of iscador: A Viscum album preparation I. Hyperplasia of the thymic cortex and accelerated regeneration of hematopoietic cells following X-irradiation. Lab Invest. 1981;44:43–48
  21. Beuth J, Ko HL, Tunggal L, et al.  Thymocyte proliferation and maturation in response to galactoside-specific mistletoe lectin-1. In Vivo. 1993;7:407–410
  22. Kuttan G. Tumoricidal activity of mouse peritoneal macrophages treated with Viscum album extract. Immunol Invest. 1993;22:431–440
  23. Hamprecht K, Handgretinger R, Voetsch W, et al.  Mediation of human NK-activity by components in extracts of Viscum album. Int J Immunopharmacol. 1987;9:199–209
  24. Hajto T, Lanzrein C. Natural killer and antibody-dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients. Oncology. 1986;43:93–97
  25. Hajto T, Hostanska K, Weber K, et al.  Effect of a recombinant lectin, Viscum album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in vitro and in vivo. Nat Immun. 1998;16:34–46
  26. Hajto T, Hostanska K, Frei K, et al.  Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res. 1990;50:3322–3326
  27. Beuth J. Clinical relevance of immunoactive mistletoe lectin-I. Anticancer Drugs. 1997;8(suppl 1):S53–S55
  28. Stein GM, Pfuller U, Berg PA. Recognition of different antigens of mistletoe extracts by anti-mistletoe lectin antibodies. Cancer Lett. 1999;135:165–170
  29. Park JH, Hyun CK, Shin HK. Cytotoxic effects of the components in heat-treated mistletoe (Viscum album). Cancer Lett. 1999;139:207–213
  30. Stein GM, Schaller G, Pfuller U, et al.  Thionins from Viscum album L: Influence of the viscotoxins on the activation of granulocytes. Anticancer Res. 1999;19:1037–1042
  31. Nikolai G, Friedl P, Werner M, et al.  Effect of a mistletoe extract (Iscador QuFrF) on viability and migratory behavior of human peripheral CD4+ and CD8+ T lymphocytes in three-dimensional collagen lattices. In Vitro Cell Dev Biol Anim. 1997;33:710–716
  32. Nikolai G, Friedl P, Werner M, et al.  Donor-dependent and dose-dependent variation in the induction of T lymphocyte locomotion in a three-dimensional collagen matrix system by a mistletoe preparation (Iscador). Anticancer Drugs. 1997;8(suppl 1):S61–S64
  33. Kiene H. Klinische Studien zur Misteltherapie karzinomatoeser Erkrankungen, Eine Uebersicht. Therapeutikon. 1990;3:347–353
  34. Hauser SP. Iscador-Mistelpraeparat zur Krebsbekaempfung Dokumentation Nr. 10. Schweiz Rundschau Med (PRAXIS). 1988;77:69–74
  35. Kleijnen J, Knipschild P. Mistletoe treatment for cancer. Review of controlled trials. Phytomedicine. 1994;1:255–260
  36. Dold U, Edler L, Maeurer HC, et al.  Krebstherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom. Stuttgart, Germany: Georg Thieme Verlag; 1991;
  37. Gorter RW, van Wely M, Reif M, et al.  Tolerability of an extract of European mistletoe among immunocompromised and healthy individuals. Altern Ther Health Med. 1999;5:37–44
  38. Friess H, Beger HG, Kunz J, et al.  Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Anticancer Res. 1996;16:915–920
  39. Heiny BM, Beuth J. Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res. 1994;14:1339–1342
  40. Lenartz D, Dott U, Menzel J, et al.  Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res. 2000;20:2073–2076
  41. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al.  The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: A randomised controlled clinical trial. Eur J Cancer. 2001;37:23–31
  42. Eggermont AMM, Kleeburg UR, Ruiter DJ, et al.  European Organization for Research and Treatment of Cancer Melanoma Group trial experience with more than 2,000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b. In:  Perry MC editors. American Society of Clinical Oncology Educational Book. Spring 2001. Alexandria, VA: ASCO; 2001;p. 88–93
  43. Piscitelli SC, Burstein AH, Chaitt D, et al.  Indinavir concentrations and St John's wort. Lancet. 2000;355:547–548
  44. Gabius HJ, Darro F, Remmelink M, et al.  Evidence for stimulation of tumor proliferation in cell lines and histotypic cultures by clinically relevant low doses of the galactoside-binding mistletoe lectin, a component of proprietary extracts. Cancer Invest. 2001;19:114–126
  45. Kjaer M. Mistletoe therapy of metastasizing renal cancer. A phase II study. Ugeskr Laeger. 1988;150:1923–1928
  46. Grossarth-Maticek R, Eysenck HJ. Coca-Cola, cancers, and coronaries: Personality and stress as mediating factors. Psychol Rep. 1991;68:1083–1087
  47. Grossarth-Maticek R, Eysenck HJ, Barrett P. Prediction of cancer and coronary heart disease as a function of method of questionnaire administration. Psychol Rep. 1993;73:943–959
  48. Grossarth-Maticek R, Eysenck HJ. Creative novation behaviour therapy as a prophylactic treatment for cancer and coronary heart disease: Part I—Description of treatment. Behav Res Ther. 1991;29:1–16
  49. Grossarth-Maticek R, Eysenck HJ, Boyle GJ. Method of test administration as a factor in test validity: The use of a personality questionnaire in the prediction of cancer and coronary heart disease. Behav Res Ther. 1995;33:705–710
  50. Grossarth-Maticek R, Eysenck HJ, Boyle GJ, et al.  Interaction of psychosocial and physical risk factors in the causation of mammary cancer, and its prevention through psychological methods of treatment. J Clin Psychol. 2000;56:33–50

☆ Address reprint requests to Patrick J. Mansky, MD, Laboratory of Clinical Investigation, National Center for Complementary and Alternative Medicine (NCCAM), National Institutes of Health, 8 West Dr, Quarters 15-B1, MSC 2669, Bethesda, MD 20892.

☆☆ This is a US government work. There are no restrictions on its use.

PII: S0093-7754(02)50322-5

doi: 10.1053/sonc.2002.50006

Seminars in Oncology
Volume 29, Issue 6 , Pages 589-594 , December 2002

Article Tools